Once-daily fexofenadine treatment for chronic idiopathic urticaria: A multicenter, randomized, double-blind, placebo-controlled study

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 6, 2005, Pages 662-669

  Kaplan, Allen P ^a   Spector, Sheldon L ^b   Meeves, Suzanne ^c   Liao, Yuning ^c   Varghese, Santosh T ^c   Georges, George ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 20544453784     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61325-7     Document Type: Article

References (37)

1. Greaves MW, O'Donnell BF, Winkelmann RK. Chronic urticaria: evidence for autoimmunity. Allergy Clin Immunol News. 1995;7:36-33.
2. Barnetson R. Allergy and the skin. In: Lessof M, ed. Allergy: Immunological and Clinical Aspects. New York, NY: John Wiley & Sons; 1994:219-222.
3. Mathews KP. The urticarias: current concepts in pathogenesis and treatment. Drugs. 1985;30:552-550.
4. Warin RP. Food factors in urticaria. J Hum Nutr. 1976;30: 179-186.
5. Demera RS, Ryhal B, Gershwin ME. Chronic idiopathic urticaria. Comp Ther. 2001;27:213-217.
6. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 2003;3:363-368.
7. Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;329:599-604.
8. Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol. 1988;90:213-217.
9. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001; 107:1056-1062.
10. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136:197-201.
11. Negro-Alvarez JM, Miralles-Lopez JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol (Madr). 2001;29: 129-132.
12. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc. 2000;21:15-20.
13. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs. 2001;61:207-236.
14. Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998;55: 269-274.
15. Paul E, Berth-Jones J, Ortonne J-P. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treatment. 1998;9:143-149.
16. Finn AF Jr, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104: 1071-1078.
17. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84:517-522.
18. Kulthanan K, Gritiyarangsan P, Sitakalin C. Multicenter study of the efficacy and safety of fexofenadine 60 mg twice daily in 108 Thai patients with chronic idiopathic urticaria. J Med Assoc Thai. 2001;84:153-159.
19. Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol. 2002;41:701-706.
20. Degonda M, Pichler WJ, Bircher A, et al. Chronic idiopathic urticaria: effectiveness of fexofenadine: a double-blind, placebo-controlled study with 21 patients. Schweiz Rundsch Med Prax. 2002;91:637-643.
21. Kaplan AP. Clinical practice: chronic urticaria and angioedema. N Engl J Med. 2002;346:175-179.
22. Greaves M. Chronic urticaria. Curr Rev Allergy Clin Immunol. 2000;105:664-672.
23. Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol. 2002;23:233-241.
24. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14:17-21.
25. Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. Eur J Dermatol. 2000;10:205-211.
26. Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol. 1995;33:192-198.
27. Tharp MD. Cetirizine: a new therapeutic alternative for chronic urticaria. Cutis. 1996;58:94-98.
28. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40:72-76.
29. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48:535-541.
30. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111:S835-S842.
31. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy. 1999;29(suppl 3):133-142.
32. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp. 2000;15:S3-S30.
33. Mann RD, Pearce GL, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000;320:1184-1187.
34. Desloratadine (Clarinex). Med Lett Drugs Ther. 2002;44:27-28.
35. Ridout F, Meadows R, Johnsen S, et al. Effects of desloratadine 5, 10 and 20 mg, and promethazine 25 mg on cognitive and psychomotor performance [abstract]. Ann Allergy Asthma Immunol. 2003;90:124. Abstract P35.
36. Howarth PH. The choice of an H1 antihistamine for the 21st century. Clin Exp Allergy Rev. 2002;2:1-8.
37. Ramaekers J, Vermeeren A. All antihistamines cross blood-brain barrier. BMJ. 2000;321:572.